Uterine Leiomyoma (Uterine Fibroids) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018
- January 2018 •
- 60 pages •
- Report ID: 5028359
DelveInsight’s, “Uterine Leiomyoma (Uterine Fibroids) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" report provides comprehensive insights about marketed and Phase III products for Uterine Leiomyoma (Uterine Fibroids) .
The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.
Global API Manufacturers of Marketed Products for Uterine Leiomyoma (Uterine Fibroids)
Coverage of API manufacturers for Uterine Leiomyoma (Uterine Fibroids) marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location.
Emerging Phase III products for Uterine Leiomyoma (Uterine Fibroids)
This report provides a comprehensive understanding of the emerging Phase III therapies for Uterine Leiomyoma (Uterine Fibroids) which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary information and data has been collected from various printable and non-printable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and available databases.
• A review of the marketed products for Uterine Leiomyoma (Uterine Fibroids) including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2020 and API manufacturer details.
• Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details
• API manufacturers for the marketed products with location details
• Emerging Phase III product profiles for Uterine Leiomyoma (Uterine Fibroids) including product description, developmental activities, licensors & collaborators and chemical information
Reasons to Buy
• API intelligence for marketed drugs for the indication and gaining insights of API manufacturers
• Evaluate the marketing status and patent details of products to exploit opportunities for generic drug development
• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to the indication
• Establish a comprehensive understanding of the emerging Phase III products which can be future competitors in this space